Clinical Trials Logo

Advanced Malignant Neoplasm clinical trials

View clinical trials related to Advanced Malignant Neoplasm.

Filter by:

NCT ID: NCT01549067 Recruiting - Colorectal Cancer Clinical Trials

The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey

Sprit
Start date: September 2011
Phase: N/A
Study type: Observational

Collect the real clinical background of advanced colorectal cancer c of China.

NCT ID: NCT01531361 Completed - Clinical trials for Advanced Malignant Neoplasm

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Start date: February 6, 2012
Phase: Phase 1
Study type: Interventional

This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib tosylate or crizotinib may kill more cancer cells.

NCT ID: NCT00244972 Completed - Clinical trials for Advanced Malignant Neoplasm

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Start date: October 2005
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of tipifarnib when given together with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.